Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review

Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Daxor Corp (Daxor) is a biotechnology company, which offers original medical equipment for medical personnel. The company manufactures blood volume analyzers. Its flagship product, BVA-100 blood volume analyzer is an instrument to measure human blood volume. The product is used in conjunction with Volumex, a diagnostic radiopharmaceutical containing iodinated I 131 albumins. It finds application in a range of medical and surgical conditions which includes congestive heart failure, intensive care unit medicine, critical care medicine, syncope, kidney failure, hypertension, renal failure, red blood cell abnormalities, hyponatremia and other conditions. The company offers its product to hospitals, clinics, and physicians. Daxor is headquartered in Oak Ridge, the US.

Daxor Corp Key Recent Developments

Jun 15,2023: Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services
Mar 02,2023: Daxor to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update
Jan 19,2023: Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Jan 13,2023: Daxor Corporation to exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Daxor Corp - Key Facts
Daxor Corp - Key Employees
Daxor Corp - Key Employee Biographies
Daxor Corp - Major Products and Services
Daxor Corp - History
Daxor Corp - Company Statement
Daxor Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Daxor Corp - Business Description
Daxor Corp - SWOT Analysis
SWOT Analysis - Overview
Daxor Corp - Strengths
Daxor Corp - Weaknesses
Daxor Corp - Opportunities
Daxor Corp - Threats
Daxor Corp - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Daxor Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
Daxor Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023
Daxor Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 15, 2023: Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services
Mar 02, 2023: Daxor to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update
Jan 19, 2023: Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Jan 13, 2023: Daxor Corporation to exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress
Sep 26, 2022: Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America
Sep 06, 2022: Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022: Daxor to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update
Aug 24, 2022: Daxor Corp to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update
May 12, 2022: Daxor to Present at the H.C. Wainwright & Company Global Investment Conference
Mar 23, 2022: Daxor Corp to Participate in the Maxim Group 2022 Virtual Growth Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Daxor Corp, Key Facts
Daxor Corp, Key Employees
Daxor Corp, Key Employee Biographies
Daxor Corp, Major Products and Services
Daxor Corp, History
Daxor Corp, Subsidiaries
Daxor Corp, Key Competitors
Daxor Corp, Ratios based on current share price
Daxor Corp, Annual Ratios
Daxor Corp, Annual Ratios (Cont...1)
Daxor Corp, Interim Ratios
Daxor Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
Daxor Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023
Daxor Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Daxor Corp, Performance Chart (2018 - 2022)
Daxor Corp, Ratio Charts
Daxor Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
Daxor Corp, Medical Equipment, Deals by Type, 2017 to YTD 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings